Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 10/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392852 | 1.00 | HDAC1 (0.49) | HDAC1HDAC6UCHL1ARUSP30 | |
| SCHEMBL31161840 | 0.84 | UCHL1 (0.45) | HDAC1HDAC6UCHL1ARUSP30 | |
| SCHEMBL30392612 | 0.81 | UCHL1 (0.45) | UCHL1USP30NOTUMGPR119 | |
| SCHEMBL26098666 | 0.81 | UCHL1 (0.45) | UCHL1USP30NOTUMGPR119 | |
| SCHEMBL31161341 | 0.80 | UCHL1 (0.45) | HDAC1HDAC6UCHL1USP30NOTUM | |
| SCHEMBL30955281 | 0.78 | HDAC1 (0.53) | HDAC1HDAC6UCHL1ARUSP30 | |
| SCHEMBL2022337 | 0.78 | HDAC1 (0.53) | HDAC1HDAC6UCHL1ARUSP30 | |
| SCHEMBL26099961 | 0.76 | UCHL1 (0.50) | UCHL1ARUSP30NOTUMKMT2A | |
| SCHEMBL31161891 | 0.76 | UCHL1 (0.47) | HDAC1HDAC6UCHL1USP30NOTUM | |
| SCHEMBL30955317 | 0.75 | UCHL1 (0.54) | UCHL1USP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | HDAC1 1497/4885HDAC6 875/4885UCHL1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.